Bryan Maloney

Bryan Maloney

Auto-generated profile, based on publicly available information

Bryan Maloney

Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, Lexington, KY 40536, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2008 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JWJinfang Wu
Jinfang Wu
RBRiyaz Basha
Riyaz Basha
BBBrian Brock
Brian Brock
DCDavid P. Cox
David P. Cox
FCFernando Cardozo-Pelaez
Fernando Cardozo-Pelaez
NZNasser H. Zawia
Nasser H. Zawia
The sporadic nature of Alzheimer's disease (AD) argues for an environmental link that may drive AD pathogenesis; however, the triggering factors and the period of their action are unknown. Recent studies in rodents have shown that exposure to lead (Pb) during brain development predetermined the expression and regulation of the amyloid precursor protein (APP) and its amyloidogenic β-amyloid (Aβ) product in old age. Here, we report that the expression of AD-related genes [APP, BACE1 (β-site APP cleaving enzyme 1)] as well as their transcriptional regulator (Sp1) were elevated in aged (23-year-old) monkeys exposed to Pb as infants. Furthermore, developmental exposure to Pb altered the levels, characteristics, and intracellular distribution of Aβ staining and amyloid plaques in the frontal association cortex. These latent effects were accompanied by a decrease in DNA methyltransferase activity and higher levels of oxidative damage to DNA, indicating that epigenetic imprinting in early life influenced the expression of AD-related genes and promoted DNA damage and pathogenesis. These data suggest that AD pathogenesis is influenced by early life exposures and argue for both an environmental trigger and a developmental origin of AD.

1 March 2008 in Neuron
Verified
Journal Article
Closed access
YWYi Wen
Yi Wen
WYW. Haung Yu
W. Haung Yu
BMBryan Maloney
Bryan Maloney
JBJason Bailey
Jason Bailey
JMJunrong Ma
Junrong Ma
KDKaren Duff
Karen Duff

22 October 2009 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DLDebomoy K. Lahiri
Debomoy K. Lahiri
BMB Maloney
B Maloney
NZN H Zawia
N H Zawia
Neurobiological disorders have diverse manifestations and symptomology. Neurodegenerative disorders, such as Alzheimer's disease, manifest late in life and are characterized by, among other symptoms, progressive loss of synaptic markers. Developmental disorders, such as autism spectrum, appear in childhood. Neuropsychiatric and affective disorders, such as schizophrenia and major depressive disorder, respectively, have broad ranges of age of onset and symptoms. However, all share uncertain etiologies, with opaque relationships between genes and environment. We propose a ‘Latent Early-life Associated Regulation’ (LEARn) model, positing latent changes in expression of specific genes initially primed at the developmental stage of life. In this model, environmental agents epigenetically disturb gene regulation in a long-term manner, beginning at early developmental stages, but these perturbations might not have pathological results until significantly later in life. The LEARn model operates through the regulatory region (promoter) of the gene, specifically through changes in methylation and oxidation status within the promoter of specific genes. The LEARn model combines genetic and environmental risk factors in an epigenetic pathway to explain the etiology of the most common, that is, sporadic, forms of neurobiological disorders.

1 April 2004 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KSKumar Sambamurti
Kumar Sambamurti
RKRachel Kinsey
Rachel Kinsey
BMBryan Maloney
Bryan Maloney
YGYuan-Wen Ge
Yuan-Wen Ge
DLDebomoy K. Lahiri
Debomoy K. Lahiri
The first step in the generation of the amyloid‐β peptide (Aβ) deposited in the brains of patients with Alzheimer's disease (AD) is the processing of the larger Aβ precursor protein (APP) by an integral membrane aspartyl protease named the β‐site APP‐cleaving enzyme (BACE). We present the genomic organization of the BACE gene. BACE mRNAs are synthesized as nine exons and eight introns from a 30.6 kb region of chromosome 11q23.2–11q23.3. Regulation of BACE may play an important role in regulating the levels of Aβ produced and is therefore likely to play an important role in AD. Herein, we report the cloning and detailed analysis of 3765 nucleotides of the promoter region of BACE and 364 nucleotides of the 5′ untranslated region of the BACE mRNA (5′ UTR). Characteristic “CAAT” and “TATA” boxes are absent within 1.5 kb of the transcription start site (TSS). The promoter region and 5′ UTR contain multiple transcription factor binding sites, such as activator protein (AP)1, AP2, cAMP response element binding protein (CREB), estrogen responsive element (ERE), glucocorticoid responsive element (GRE), “GC” box, nuclear factor (NF)‐κB, signal transducer and activator of transcription (STAT)1, stimulating protein (SP)1, metal‐regulatory elements, and possible Zeste binding sites. Limited interspecies similarity was observed between the human sequence and corresponding genomic DNA from the rat and mouse sequences, but several transcription factor‐binding sites are conserved. Thus, the BACE gene contains basal regulatory elements, inducible features and sites for regulated activity by various transcription factors. These results identify the important regions for functional analysis of the binding domains and neuron‐specific expression (1). Such a study will allow us to further examine the possible role of changes in the promoter of BACE in AD pathogenesis.

12 April 2011 in Neurology
Verified
Journal Article
Closed access
DSD.K. Sokol
D.K. Sokol
BMB. Maloney
B. Maloney
JLJ.M. Long
J.M. Long
BRB. Ray
B. Ray
DLDebomoy K. Lahiri
Debomoy K. Lahiri
The present review highlights an association between autism, Alzheimer disease (AD), and fragile X syndrome (FXS). We propose a conceptual framework involving the amyloid-β peptide (Aβ), Aβ precursor protein (APP), and fragile X mental retardation protein (FMRP) based on experimental evidence. The anabolic (growth-promoting) effect of the secreted α form of the amyloid-β precursor protein (sAPPα) may contribute to the state of brain overgrowth implicated in autism and FXS. Our previous report demonstrated that higher plasma sAPPα levels associate with more severe symptoms of autism, including aggression. This molecular effect could contribute to intellectual disability due to repression of cell-cell adhesion, promotion of dense, long, thin dendritic spines, and the potential for disorganized brain structure as a result of disrupted neurogenesis and migration. At the molecular level, APP and FMRP are linked via the metabotropic glutamate receptor 5 (mGluR5). Specifically, mGluR5 activation releases FMRP repression of APP mRNA translation and stimulates sAPP secretion. The relatively lower sAPPα level in AD may contribute to AD symptoms that significantly contrast with those of FXS and autism. Low sAPPα and production of insoluble Aβ would favor a degenerative process, with the brain atrophy seen in AD. Treatment with mGluR antagonists may help repress APP mRNA translation and reduce secretion of sAPP in FXS and perhaps autism.

16 February 2006 in The FASEB Journal
Verified
Journal Article
Closed access
CBCeleste M. Bolin
Celeste M. Bolin
RBRiyaz Basha
Riyaz Basha
DCDavid Cox
David Cox
NZNasser H. Zawia
Nasser H. Zawia
BMBryan Maloney
Bryan Maloney
FCFernando Cardozo‐Pelaez
Fernando Cardozo‐Pelaez